Malignant pleural mesothelioma (MPM), an aggressive malignancy affecting pleural surfaces, occurs in three main histological subtypes. The epithelioid and sarcomatoid subtypes are characterized by cuboid and fibroblastoid cells, respectively. The biphasic subtype contains a mixture of both. The sarcomatoid subtype expresses markers of epithelialmesenchymal transition (EMT) and confers the worst prognosis, but the signals and pathways controlling EMT in MPM are not well understood. We demonstrate that treatment with FGF2 or EGF induced a fibroblastoid morphology in several cell lines from biphasic MPM, accompanied by scattering, decreased cell adhesion and increased invasiveness. This depended on the MAP-kinase pathway but was independent of TGFβ or PI3-kinase signaling. In addition to changes in known EMT markers, microarray analysis demonstrated differential expression of MMP1, ESM1, ETV4, PDL1 and BDKR2B in response to both growth factors and in epithelioid versus sarcomatoid MPM. Inhibition of MMP1 prevented FGF2-induced scattering and invasiveness. Moreover, in MPM cells with sarcomatoid morphology, inhibition of FGF/MAP-kinase signaling induced a more epithelioid morphology and gene expression pattern. Our findings suggest a critical role of the MAP-kinase axis in the morphological and behavioral plasticity of mesothelioma. K.Schelch et al. | 535 
Introduction
Malignant pleural mesothelioma (MPM) is a very aggressive malignancy arising from the mesothelial cells lining the pleural cavity (1) . Inhalation of asbestos fibers is the main cause of MPM. Industrial use of asbestos has led to a rise in incidence during the second half of the 20th century (2) . A further global increase is expected due to continued mining and use of asbestos in many countries and the long latency period between asbestos exposure and clinical manifestation of MPM (3) .
Histologically, MPM is classified as either epithelioid, sarcomatoid or biphasic (also termed mixed). The median survival of patients is between 9 and 17 months (4). However, the epithelioid subtype confers better prognosis than the biphasic or sarcomatoid subtype and may also show a more favorable response to therapy (5, 6) . Current first-line chemotherapy for MPM usually consists of a combination of cisplatin and pemetrexed, and prolongs median survival by several months (7) . In selected patients with early-stage disease, multimodality therapy combining surgery, chemotherapy and radiation is feasible and is likely to further prolong survival (8) . Local tumor spread and invasion into surrounding tissue in combination with resistance to radiation and chemotherapy often cause rapid tumor recurrence leaving limited treatment options (9, 10) .
Several studies have suggested that the different histological subtypes of MPM may reflect the occurrence of epithelial-mesenchymal transition (EMT) (11-13), a cellular program by which epithelial cells acquire the morphology and behavioral characteristics of mesenchymal, fibroblast-like cells (14) . EMT not only plays a fundamental role during embryogenesis but also contributes to tumor progression by promoting cell migration and invasion. Some prototypical EMT markers like E-cadherin, Snail or ZEB1 are differentially expressed between epithelioid and sarcomatoid MPM (11, 12) , and a genome-wide expression study demonstrated an EMT signature in a subgroup of MPM cases, which was associated with a worse prognosis (15) . These data suggest that EMT plays an important role in a subset of MPM patients and may critically affect prognosis and therapy response. However, the triggering signals and associated signal transduction pathways of EMT in MPM cells are not well understood.
In this study, we investigate growth factor-induced EMT in MPM and characterize the underlying pathways and target genes in cell models and tissue specimens. Moreover, we describe the possibility for reversal of mesenchymal/sarcomatoid features by inhibition of specific pathways.
Materials and methods

Cell culture
Cell lines were cultivated in growth medium containing 10% heat-inactivated fetal bovine serum (FBS) in a humidified atmosphere (37°C, 5% CO 2 ). Growth media and information on all cell lines used are listed in Supplementary Table 1, available at Carcinogenesis Online. Unless stated otherwise, all experiments were performed in medium with 10% FBS. Cell lines were authenticated by array comparative genomic hybridization or STR profiling, and experiments were performed within <10 passages after authentication and <15-20 passages after establishment or receipt from collaborators or commercial suppliers.
Cytokines and drugs
All inhibitors, their target molecules and the commercial suppliers of all cytokines and inhibitors used are listed in Supplementary Tables 2 and 3 , available at Carcinogenesis Online. FGF2, EGF and other cytokines were used at 10 ng/ml except for adhesion assays (20 ng/ml) and invasion and soft agar assays (50 ng/ml) where higher cytokine concentrations were used to account for the initially unattached cell state and protein degradation during prolonged incubation, respectively.
Morphology analysis
MPM cells (1 × 10 5 ) were seeded into six-well plates and treated the next day with FGF2, FGF18, EGF, HGF, PDGF-AB, TGFβ1 or BMP2 at a concentration of 10 ng/ml in medium with 10% FBS or serum-free medium. For combination treatment, the FGFR inhibitors PD-166866 (10 µM) and BGJ-398 (0.5 µM), the mulitkinase (including FGFR) inhibitors nintedanib (0.5 µM) and ponatinib (0.5 µM), the EGFR inhibitor erlotinib (10 µM), the AKT inhibitor MK-2206 (10 µM), the PI3K inhibitor LY-294002 (20 µM), the MEK inhibitors UO-126 (10 µM) and selumetinib (10 µM), the TGFβ-receptor inhibitor SB-431542 (20 µM), the focal adhesion kinase (FAK) inhibitor BI-853520 (1 µM), the NFκB inhibitor BAY-11-7082 (1 µM), the MMP inhibitor GM6001 (5 µM) and the ETS family inhibitor YK4-279 (1 µM) were added 1 h before cytokines. Concentrations were chosen following literature reports and did not induce cytotoxicity over the duration of analysis. Microscopic images were taken 24 h later using a Nikon microscope (Eclipse Ti300) and a Nikon DS Fi1c camera. Aspect ratio (major axis/minor axis) and circularity [4π (area/perimeter) 2 ] of about 120 individual cells, and area and perimeter of cell clusters were analyzed with ImageJ or Adobe Photoshop CS4. To quantitate the degree of cell scattering, a key characteristic of EMT in cultured cells (16) , the numbers of contiguous cell clusters (cell islands with cell-cell contacts) per microscopic image of at least three independent experiments were counted using ImageJ and defined as 'scatter score.'
Immunoblots
MPM cells (1 × 10 5 ) were seeded into six-well plates in medium with 10% FBS and incubated with FGF2, EGF or vehicle (phosphate-buffered saline). Cells were harvested in lysis buffer (150 mM NaCl, 50 mM HEPES, 10% glycerol, 1 mM EDTA, 0.5 mM Na 3 VO 4 , 10 mM NaF, 1% Triton X100, 1.5 mM MgCl 2 ), proteins (15-30 µg) were separated by SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes. Immunoblots were performed as described previously (17) . Briefly, membranes were stained with Ponceau S to control for equal sample loading, blocked in tris-buffered saline with Tween 20 and 5% skim milk powder or bovine serum albumin (dependent on recommendations of the antibody suppliers) and incubated in primary antibodies at 4°C overnight. Primary antibodies used, their suppliers, IDs and dilutions are listed in Supplementary Table 4 , available at Carcinogenesis Online. After washing, membranes were incubated with horseradish peroxidase-coupled secondary antibodies (Dako, Glostrup, Denmark, 1:10,000) for 1 h at ambient temperature. Signals were developed with the Immun-Star Western C Chemiluminescence kit (Biorad, Hercules, CA).
Adhesion assays
For quantification of adhesion, cells stably expressing green fluorescent protein (GFP) after retroviral transduction were used. The GFP cDNA was subcloned into the retroviral vector pQCXIP (Clontech Mountain View, CA) as described previously (18) . Viral particles were generated with the Clontech Retro-X Universal Packaging System according to the manufacturer's instructions. MPM cell lines stably expressing GFP were established by incubating the MPM cells with viral particles in the presence of 8 µg/ ml polybrene overnight followed by selection with puromycin (0.8 µg/ ml) for 2 weeks. For analysis, 1 × 10 4 cells were seeded in quadruplicates into 96-well plates in medium with 10% FBS containing FGF2 or EGF. For measuring the impact on attachment speed, the medium was changed 30-120 min after seeding to remove non-attached cells and the plates were scanned on a Typhoon Trio imager (488 nm, 526/30 nm bandpass filter). To determine resistance to detachment, cells were scanned 1 day after seeding, washed with PBS (3×) and scanned again (19) . The degree of cell loss was calculated using ImageJ.
Invasion assay
Cells (4 × 10 4 ) were seeded into collagen-coated (50 µl, 1:12 in PBS, overnight at 37°C) Boyden chambers (8 µm pore size, 24-well format) in medium with 10% FBS and treated with FGF2 or EGF. After 72 h, filters were washed with PBS, fixed with methanol/acetic acid (3:1), and cells on the upper side of the membrane were removed. Cells on the underside of the membrane were stained with crystal violet that was subsequently solubilized in 2% SDS. Absorbance was read at 562 nm on a Synergy HT microplate reader.
Soft agar assay
Anchorage-independent growth was assessed by soft agar assay. Briefly, a bottom layer of 1.5 ml growth medium containing 0.6% agar was poured into six-well plates. The next day, 5 × 10 3 cells were suspended in 1.5 ml medium (with 10% FBS) containing 0.3% agar, treated with FGF2 or EGF and added as top layer. Plates were incubated for 17-19 days. Colonies were counted microscopically (cut-off: 100 µm diameter).
TaqMan low-density array
Expression of 760 microRNAs was assessed using TaqMan Array Human MicroRNA A+B Cards Set v3.0. Cells were seeded and treated with FGF2 for 24 h, harvested, and total RNA was extracted using TRIZOL (Thermo Fisher Scientific, Waltham, MA). cDNA synthesis was conducted using Megaplex RT Primers Human Pool Set v3.0 (Thermo Fischer Scientific) according to the manufacturer's instructions. TaqMan low-density arrays (TLDAs) were run on a ViiA7 thermocycler, and data were analyzed as described (20) .
Gene expression microarrays
To compare cell lines established from different histological MPM subtypes, cells were grown to 60-80% confluence in their respective growth media with 10% FBS before RNA isolation. For analysis of expression changes in response to growth-factor treatment, 1 × 10 5 cells were seeded into six-well plates in medium with 10% FBS and treated the next day with FGF2 or EGF for 24 h. RNA from two biological replicas each was isolated using TRIZOL and checked on an Agilent 2100 Bioanalyzer. Genome-wide mRNA expression analysis was performed using 4 × 44 whole genome gene expression arrays (Agilent Technologies, Santa Clara, CA) following the manufacturer's instructions. Arrays were scanned on an Agilent G2505B microarray scanner. Differential gene expression was analyzed using GeneSpring version 13.0.4 GX.
Pathway analysis
For both microRNA target genes and gene array (fold change >3) datasets, pathway enrichment analysis was carried out. The microRNA dataset was derived from target gene extraction (TargetScan v6.2) of differentially expressed microRNAs (fold change >10) based on Fisher's exact test. Similarly, differentially expressed genes (fold change >3) from the transcriptome dataset were used. Enriched pathways were built based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Partek Genomics Suite v6.5, St Louis, MO).
PCR analysis
Cells (1 × 10 5 ) were seeded in medium with 10% FBS and treated as described in the Morphology analysis section. RNA was isolated with TRIZOL 24 h after cytokine treatment and reverse transcribed with M-MLV reverse transcriptase (Thermo Fisher Scientific) and random hexamer primers. The resulting cDNAs were analyzed using TaqMan gene expression assays or SYBR-based quantitative real-time PCR (qPCR) (Thermo Fisher Scientific) on an Applied Biosystems 7500 Fast Real-Time PCR System. TaqMan assay IDs and primer sequences are listed in Supplementary Tables 5 and 6 , available at Carcinogenesis Online. Changes in gene expression are shown as log2 of 2 −ΔΔCt compared with the respective untreated controls and normalized to GAPDH as reference gene. 
Transfection with siRNAs
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue specimens (n = 13) from MPM as well as two normal pleura controls were immunostained as described previously (21) . Briefly, tissue sections (cut at 4 µM) were deparaffinized and rehydrated. Antigen retrieval was performed for 10 min in 10 mM citrate buffer (pH 6.0), and sections were incubated overnight at 4°C with primary antibodies for pERK (#4370, Cell Signaling, Danvers, MA, 1:200) and MMP1 (EP1247Y, Abcam, Cambridge, UK, 1:100). Antibody binding was detected by means of the UltraVision LP detection system (Lab Vision Corporation, Fremont, CA). Representative images (×40) were taken using the Pannoramic Viewer software and a Midi Slide Scanner (Brightfield mode, auto settings, ×40, 3DHistech, Budapest, Hungary). Results were evaluated by an experienced pathologist, and H-scores were calculated as the product percentage of positive tumor cells and staining intensity (0-3).
Statistical analysis
Data are presented as means ± SEM of at least three independent experiments performed in duplicates. Statistical significance was calculated with Prism5.0 (GraphPad, San Diego, CA). A P-value of <0.05 was considered significant.
Results
Treatment with FGF2 or EGF induces scattering and morphology changes in MPM cell lines
We have previously observed that FGF2 treatment induced increased MPM cell proliferation and migration, promoted scattering and produced a spindle-shaped morphology in M38K and SPC212 cells within 24 h (17). Here, we confirm the phenotypical alterations in three additional cell lines established from biphasic MPM ( Figure 1A ). We further characterized these morphological alterations in M38K and found significant changes in aspect ratio, circularity of single cells and in the area/circumference ratios of cell clusters, reflecting the elongated, fibroblastoid cell shape and the scattering upon FGF2 treatment, respectively ( Figure 1B) . We also used the number of contiguous cell clusters per image that we termed 'scatter score. ' We found that treatment with FGF2 for 5 min is sufficient for scattering and morphology changes to be observable 24 h later ( Figure 1C 
The MAPK pathway, but not the PI3K/AKT pathway or TGFβ receptor signaling, is required for scattering and morphology changes
To identify the signaling pathways required for the observed effects, we pretreated the cells with inhibitors of EMT-related pathways. As expected, FGFR inhibitors prevented the effects of FGF2 but not those of EGF and vice versa ( Figure 1E ). Inhibitors of the downstream MAPK pathway prevented effects induced by FGF2 or EGF, whereas inhibitors of the PI3K/AKT pathway had no effect. Also inhibition of TGFβ receptors, NFκB and FAK did not prevent FGF2-induced effects ( Figure 1F ). Immunoblotting 
FGF2 or EGF treatment increases invasion and decreases adhesion
Fibroblastoid cell morphology is often accompanied by migratory and invasive cell behavior and decreased adhesion (22, 23) . Fittingly, FGF2 stimulates migration of M38K and SPC212 cells (17) , and we next tested the impact on adhesion to the substratum. Indeed, FGF or EGF led to reduced connection to culture plates 24 h after treatment ( Figure 2A ) and slowed down the attachment of cells to the plate surface when seeded in growth factor-containing medium (SPC212 and MM05 cells, Supplementary Figure 5 , available at Carcinogenesis Online). Moreover, FGF2 and EGF stimulated invasion through a collagen matrix ( Figure 2B ) and anchorage-independent growth in soft agar ( Figure 2C ). In SPC212, clones in soft agar also had a more scattered appearance when treated with FGF2 or EGF ( Figure 2C ).
FGF2 or EGF treatment induces gene expression changes reflecting EMT and histological subtypes of MPM
To investigate gene expression programs underlying the observed morphological and behavioral changes, we used whole genome gene expression microarrays of M38K and SPC212 cells treated with FGF2 or EGF. The expression of 39 genes was regulated (>3-fold) in both cell models by FGF2 and 33 by EGF ( Figure 3A) . Nineteen genes overlapped all four groups. Changes in microRNA expression were assessed with TLDAs in FGF2-treated M38K and SPC212 cells. Twelve microRNAs were commonly regulated (>10-fold) in both cell models ( Figure 3B ). Categories identified by pathway enrichment analysis to contain multiple regulated genes included transcriptional misregulation in cancer, complement and coagulation cascades and ECMreceptor interaction ( Figure 3C , Supplementary Table 7 , available at Carcinogenesis Online). Targets of FGF2-regulated microRNAs were connected to MAPK, Wnt and Hippo signaling and to focal adhesion and tight junctions ( Figure 3C , Supplementary Table 8 , available at Carcinogenesis Online). In line with the morphological changes, genes regulated by FGF2 or EGF included several classic EMT markers ( Figure 3D ). A list of core EMT genes from a meta-analysis of EMT signatures across multiple cell models (24) contained 14 up-and 24 downregulated genes matching our microarray data in both M38K and SPC212 cells treated with FGF2 and EGF (Supplementary Tables 9 and 10 , available at Carcinogenesis Online).
Next, we compared the grouped gene signature of all treated samples and their vehicle-treated controls with grouped expression array data of cell lines established from epithelioid (n = 15) and sarcomatoid (n = 3) MPM. In unsupervised clustering, the treated group clustered with the sarcomatoid group and the control group with the group of epithelioid cell lines ( Figure 4A ). Genes that were affected by growth factor treatment (>3-fold and P < 0.05) and, in addition, showed differential expression between epithelioid and sarcomatoid cell lines included bradykinin receptor B2 (BDKRB2), matrix metalloproteinase 1 (MMP1), integrin subunit alpha 6 (ITGA6), endocan (ESM1) and the immune checkpoint protein programmed death ligand 1 (PDL1, CD274) ( Figure 4B) . Regulation of selected genes by FGF2 or EGF and dependency on downstream pathways was further analyzed in M38K by qPCR. MAPK inhibition resulted in complete reversal of FGF2 or EGF-induced gene expression changes ( Figure 4C, Supplementary Figure 6 , available at Carcinogenesis Online). Conversely, PI3K inhibition had either minor or similar effects compared with the growth factors themselves.
Inhibition or silencing of MMP1 but not of ESM1 or Ets-family transcription factors prevents FGF2-induced scattering
Since MMP1, ESM1 and the Ets-family transcription factor ETV4 were all strongly upregulated concurrent with the morphological and behavioral changes ( Figure 4C, Supplementary Figure 7 , available at Carcinogenesis Online), we tested their functional relevance in this respect. The pan-MMP inhibitor GM6001 as well as MMP1-targeting siRNA prevented FGF2-induced morphological changes and scattering, while the Ets-family inhibitor YK4-279 or ESM1-targeting siRNA had no effect ( Figure 5A-C) . GM6001 also prevented FGF2-mediated invasion ( Figure 5D ).
Inhibition of FGF receptors or the MAPK pathway induces transition to epithelioid cell morphology
Since treatment with FGF2 or EGF shifted cell morphology to a more sarcomatoid phenotype, we reasoned that cell lines with fibroblastoid/sarcomatoid morphology in the untreated state might in turn be shifted to a more epithelioid morphology by inhibition of the respective pathways. Fittingly, inhibition of the FGFR axis caused an epithelioid-like shift in VMC58 (biphasic; Figure 5E ) and Meso84 (sarcomatoid; Figure 5F ). Similar changes were induced by MEK inhibitors but not by inhibition of PI3K/ Akt, EGFR, NFκB or FAK ( Figure 5E and F) . The FGFR inhibitorinduced shift towards epithelioid morphology was accompanied by strong upregulation of the epithelial marker CDH1 and downregulation of ESM1 and (in VMC58) MMP1, whereas other markers were affected to a lesser degree ( Figure 5G and H) . The shift toward a more epithelioid morphology in response to FGFR inhibitors was confirmed in Meso62 and Meso 80, two additional cell lines from sarcomatoid MPM (Supplementary Figure 8 , available at Carcinogenesis Online).
Sarcomatoid appearance is associated with MAPKregulated gene expression in MPM cell lines and tissue specimens
To further explore the regulation of gene expression in the context of epithelioid versus sarcomatoid morphology, we compared the response to FGF2, EGF and FGFR inhibitors in cell lines with different morphologies. Generally, mRNAs that were upregulated by growth factors (MMP1, ESM1, ETV4) were strongly repressed by FGFR inhibitors, whereas downregulated mRNAs (BDKRB2, CDH1) were upregulated by FGFR inhibition ( Figure 6A ). Aligning cells based on aspect ratios revealed that the sarcomatoid phenotype was associated with higher basal ERK phosphorylation ( Figure 6B and C) as well as increased levels of MMP1, ESM1, ETV4, ITGA6 and PDL1 and decreased levels of BDKRB2 ( Figure 6D, Supplementary Figure 9 , available at Carcinogenesis Online).
We further investigated ESM1/endocan protein expression in human serum samples (n = 32) via ELISA. However, no differential expression was observed compared with healthy controls or between subtypes (Supplementary Figure 10, available at Carcinogenesis Online). Immunohistochemical analysis of pERK and MMP1 in MPM tissue specimen (n = 13) also revealed no significant difference between histological subtypes due to high heterogeneity of staining between individual samples (data not shown). However, in the four biphasic tumors of that panel, we observed a trend towards higher ERK phosphorylation and MMP1 expression in the sarcomatoid compartments compared with the epithelioid compartments ( Figure 6E ). Normal pleura (n = 2) was weakly positive for MMP1 and negative for pERK (Supplementary Figure 11 , available at Carcinogenesis Online). Finally, when the grouped gene expression profiles of growth factor-treated samples versus the respective vehicle-treated counterparts were compared with published gene expression profiles of tissue samples from sarcomatoid and epithelioid MPM (25) , the group of sarcomatoid tumors clustered with the group of growth factor-treated samples, whereas the group of epithelioid tumors clustered with the group of vehicle-treated controls (Supplementary Figure 12 , available at Carcinogenesis Online).
Discussion
EMT is a complex cellular program, which can be triggered in a context-dependent way by different signals. The most prominent inducers of EMT are TGFβ and additional members of the TGFβ family like BMPs, as well as ligands for receptor tyrosine kinases including EGF, FGFs, HGF or PDGFs (26, 27) . Cytokine concentrations inducing EMT in cultured cells (28, 29) usually exceed those found in human plasma. However, these cytokines act in a paracrine or autocrine fashion, and active concentrations at the cell surface in vivo are likely to be higher than plasma levels. In the cell lines from biphasic MPM described here, only FGF2 and EGF, but not TGFβ or BMP2, induced a transition of cell morphology and behavior resembling EMT. Moreover, blocking TGFβ receptors did not prevent FGF2-or EGF-induced changes, indicating that a contribution from autocrine TGFβ signaling is not required for EMT in these MPM cell lines.
Mesothelial cells originate from the mesoderm, and although they are organized in an epithelioid fashion to form the mesothelium, they express epithelial as well as mesenchymal proteins (30) . Transition to a fibroblastoid phenotype, accompanied by changes in gene expression, has been observed in mesothelial cells under conditions of tissue damage and repair (30) (31) (32) (33) . Consistent with expression of mesenchymal markers in mesothelial cells, some typical mesenchymal genes like vimentin were expressed in the epithelioid state of our cell lines and showed only minor upregulation during the transition to a sarcomatoid morphology. Likewise, comparison with a list of EMT genes from a meta-analysis of predominantly TGFβ-driven EMT models (24) revealed only a partial overlap with our data. This may be explained by the lack of FGF/EGF-induced EMT models in that list or be due to the mesodermal origin of mesothelial cells.
Cells of the sarcomatoid subtype of MPM (and the sarcomatoid part in biphasic tumors) have fibroblastoid features, and indeed, immunohistochemical analysis has shown that sarcomatoid MPM displays mesenchymal protein expression patterns, while epithelioid MPM expresses epithelial-like proteins (11) (12) (13) . Sarcomatoid MPM confers worse prognosis and is more resistant to therapy (13, 34) . This suggests that EMT-like reprogramming occurs in sarcomatoid and biphasic MPM and may contribute to a dismal prognosis. The underlying mechanisms, however, have remained largely unexplored so far. Consistent with the changes in cell shape and behavior, pathway enrichment analysis based on our transcriptomic and microRNA screens indicated involvement of pathways related to cell-cell and cell-matrix adhesion, cytoskeleton remodeling and growth factor signaling along the MAPK and PI3K pathway. Nevertheless, blocking of the PI3K/ Akt, NFκB and FAK pathways did not prevent EMT induction in contrast to, for instance, A549 lung adenocarcinoma cells, where TGFβ-induced EMT was blocked by inhibiting the PI3K or the MAPK pathway (35) . NFκB and FAK were previously shown to be required for transition to a mesenchymal phenotype in endothelial cells (36) and for IGF1R-induced mesenchymal morphology and EMT marker expression in triple negative breast cancer cells (37) . Of note, reversal of the fibroblastoid morphology of VMC58 and Meso84 cells was possible only with FGFR/MAPK inhibition, suggesting that neither EGFR nor PI3K signals contribute to sustaining fibroblastoid morphology in these cells. Nintedanib, an inhibitor of FGFR, VEGFR and PDGFR under clinical evaluation in MPM (e.g. NCT02568449, NCT02856425), was recently shown to reverse EMT in an ovarian cancer cell line (38) . Another FGFR1 inhibitor, PD173074, induced a shift from spindle-to cobblestone-like cell morphology in head and neck squamous cell carcinoma cells (39) .
Mesothelioma can also arise from other mesothelial membranes, most notably the peritoneal mesothelium. Although rarer than MPM, peritoneal mesothelioma shares the distribution of histological subtypes and their impact on prognosis with its pleural counterpart, thus suggesting that similar mechanisms regulating epithelial-mesenchymal plasticity might apply (40) . Moreover, inhibition of EMT is considered a promising strategy to combat invasion and metastasis in many additional tumor types including breast and lung cancer, and indeed, several inhibitors that were shown to block or reverse EMT in tumor models are currently evaluated in clinical settings (41) .
Notably, genes up-or downregulated by FGF2/EGF showed a clear association with the expression signatures of cell lines and tissue samples from sarcomatoid MPM. This suggests that cell lines established from different histological subtypes of MPM maintain distinct expression profiles in culture and identifies novel gene candidates possibly connected to different subtypes of MPM. Mutations responsible for the differentiation into distinct histological subtypes of MPM during carcinogenesis are unknown, although recent data suggest that a mutation of the TERT promoter is more frequent in sarcomatoid MPM (42) . Of note, all cell lines showing morphological alterations in response to treatment with FGF2 or EGF in our study originated from non-epithelioid MPM. The other MPM cell lines of our panel did not show EMT-like morphology changes upon FGF2 treatment (Supplementary Figure 13 and Table 11 , available at Carcinogenesis Online) despite the presence of fibroblast growth factor receptors (FGFRs) and growth-and migrationpromoting effects of FGF2 in some of these cell lines (17) . This indicates that stimulation of proliferation, migration and morphology changes by FGF2 can occur independently, which is in line with a previous report showing no correlation between proliferation and migration in MPM cell lines (43) . Due to lack of genetic traits, it is currently impossible to trace from which compartment of a biphasic tumor-specific cell lines originate. Our data suggest that cells from non-epithelioid MPM-perhaps by some genetic difference-have higher phenotypic plasticity than cells from epithelioid MPM. It is possible that stimulation with different cytokines or simultaneous stimulation with several cytokines would be required to induce EMT in epithelioid cells. This is supported by the observation that two epithelioid cell lines of our panel showed a moderate EMT-like response to TGFβ treatment (Supplementary Table 11 , available at Carcinogenesis Online).
Factors linked to EMT and histological subtype in our models included MMP1, ESM1, and ETV4. In line with a previous study (44) , we demonstrate MMP1 expression in MPM and suggest that MMP1 causally contributes to sarcomatoid morphology and increased invasiveness. ESM1, which encodes the secreted proteoglycan endocan, is expressed by endothelial cells and was found overexpressed in a number of tumor entities (45) . ESM1 was linked to tumor aggressiveness and described as a serum marker in non-small cell lung cancer (46) . Despite its obvious regulation by the FGFR/MAPK axis in MPM cell lines, ESM1 was not required for EMT, nor upregulated in the circulation of MPM patients, irrespective of histological subtype. ETV4 is a transcription factor of the ETS family and was recently linked to EMT and poor prognosis in prostate cancer via the regulation of urokinase plasminogen activator (uPA), its receptor (uPAR) and the metalloproteinases MMP2 and MMP9 (47) . While ETV4 showed a clear correlation with sarcomatoid morphology in MPM cell models, inhibition of ETS-family transcription factors alone was unable to block the FGF2-induced morphology transition.
Notably, one of the genes most strongly upregulated by both FGF2 and EGF and repressed by inhibition of the MAPK axis was PDL1, which is the target of immune checkpoint modulators (48) . In MPM, PDL1 is associated with sarcomatoid histology and gene expression signature (49, 50) . Consequently, FGFR/ EGFR/MAPK dependency of PDL1 expression should be kept in mind when considering therapies that combine MAPK pathway inhibitors with immune checkpoint modulators targeting the PD1/PDL1 axis.
In summary, our data shed new light on the phenotypic plasticity of MPM cells and suggest MAPK/MMP1 signals as important drivers of sarcomatoid morphology and gene expression in MPM.
Supplementary material
Supplementary Tables 1-11 and Figures 1-13 can be found at Carcinogenesis online. 
